Posts by Mark W. Albers, MD, PhD
-
Artificial Intelligence Identifies Candidates for Drug Repurposing in Alzheimer's Disease
Drug repurposing in Alzheimer's disease (DRIAD), a machine learning framework developed at Massachusetts General Hospital, screens currently available drugs that might serve as treatments for Alzheimer's disease—and examines unexplored targets for therapy.
-
Mass General Neurologists Research Effects of COVID-19 on the Brain
A COVID-19 smell test, a longitudinal study of patients with multiple sclerosis who develop COVID-19 and high-intensity support for the brain health of COVID-19 survivors are among the research projects underway at Massachusetts General Hospital.
Biography
Mark W. Albers is a neurologist specializing in memory and olfactory disorders. He earned a PhD in organic chemistry from Harvard University, working in the laboratory of Stuart Schreiber, and an MD degree from the H.S.T. program of Harvard Medical School and M.I.T. He was an internal medicine resident for two years at Massachusetts General Hospital and then trained in neurology at Mass General, and Brigham and Women's Hospital, where he was one of the first chief residents for the Partners neurology residency program. Following clinical training, he resumed basic research studies in the laboratory of Richard Axel and practiced behavioral neurology in the Memory Disorders Center at the Neurological Institute, affiliated with Columbia University. Following this training, he returned to Mass General where he sees outpatients in the Memory Disorders Unit and attends on the inpatient neurologic wards. His clinical research is focused on devising sensitive probes of olfactory function as a possible biomarker for early neurodegenerative disease and directly converting olfactory neuronal precursor cells from the nose into brain neurons to develop cell-based models of neurologic disease. He is a member of the Translational Neuroscience committee of the American Academy of Neurology.